CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis Setting the Stage for a New Chapter in Therapeutic Targeting

Weber, Christian and Hundelshausen, Philipp von (2017): CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis Setting the Stage for a New Chapter in Therapeutic Targeting. In: Circulation Research, Vol. 121, No. 10: pp. 1119-1121

Abstract

The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provides intriguing support for the inflammatory hypothesis of atherosclerosis and cancer in man, demonstrating diverse clinical benefits of inhibiting IL (interleukin)-1 beta for cardiovascular events and lung cancer. Limited effects on cardiovascular mortality and safety concerns raised by a higher incidence of fatal infection warrant further studies to identify patient subgroups which profit most from anti-inflammatory therapy and a careful pursuit of alternative targets.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 0009-7330
• Language: English